SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2012

 

SYNTHETIC BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada		1-12584		13-3808303
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

 

617 Detroit Street, Suite 100

Ann Arbor, Michigan 48104

(Address of principal executive offices) (Zip Code)

 

 

Registrant’s telephone number, including area code: (734) 332-7800

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 2.02 – Results of Operations and Financial Condition.

 

On August 14, 2012, Synthetic Biologics, Inc., a Nevada corporation (the “Registrant") issued the attached press release that included financial information for its second quarter ended June 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

 

Item 9.01Financial Statements and Exhibits.

 

(d)	Exhibits.
	Exhibit 99.1 Press Release issued by Synthetic Biologics, Inc. dated August 14, 2012.

 

  

 

SIGNATURES  

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	SYNTHETIC BIOLOGICS, INC.
Date: August 14, 2012	By: /s/ C. Evan Ballantyne
	Name: C. Evan Ballantyne
	Title: Chief Financial Officer

 

 

 

EXHIBIT INDEX

 

Exhibit No .	Exhibits.
99.1	Press Release issued by Synthetic Biologics, Inc. dated August 14, 2012